Elranatamab: A novel B-cell maturation T-cell engager
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on...
Shranjeno v:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2026-12-01
|
| Serija: | Human Vaccines & Immunotherapeutics |
| Teme: | |
| Online dostop: | https://www.tandfonline.com/doi/10.1080/21645515.2026.2694852 |
| Oznake: |
Brez oznak, prvi označite!
|